Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Oct 21, 2026, 7:30 AM ET
ImmunityBio announced completion of the database lock for Cohort A of QUILT-2.005 (NCT02138734), with 366 randomized patients, and expects topline results in November 2026 and an sBLA submission in Q4 2026.
Nasdaq: $IBRXCommercial-stage biotechANKTIVA · bladder cancerClinical and financing risk
IBRX Stock Hub: ImmunityBio News, ANKTIVA Sales and QUILT Data
ANKTIVA generated $50.7 million Q2 net product revenue, and the FDA expanded its U.S. label to include high-grade papillary-only BCG-unresponsive bladder cancer on October 14. The next clinical checkpoint is QUILT-2.005 topline expected in November, following database lock for 366 randomized BCG-naïve patients; no readout day has been announced. June cash and marketable securities were $357.4 million, alongside substantial liabilities, operating cash use and potential dilution. Commercial growth, clinical evidence and financing terms must be assessed together.
Research Library
The complete IBRX research report
50 pages · Research as of October 27, 2026 · Dated snapshot
Company-guided clinical window · no exact day
QUILT-2.005 topline · November 2026
The October 21 announcement reported database lock in Cohort A, with analysis underway and topline expected in November. An sBLA submission for the BCG-naïve setting was planned for Q4 2026. Database lock is a procedural step; it is not a new efficacy result or approval. Company guidance →
Separate events: November conference listings do not establish a QUILT-2.005 presentation date. The high-grade papillary-only FDA review ended with October 14 approval; January 6, 2027 is no longer a pending action date.
IBRX stock: dated key data
Reference close
$8.81
Nasdaq · October 28, 2026 regular close; $7.81 on October 26.
Calculated market value
~$9.34B
October 28 close × July 31 reported shares; warrants and awards excluded.
Q2 product revenue
$50.7M
Quarter ended June 30, 2026 · net ANKTIVA product revenue.
Cash and securities
$357.4M
June 30: $75.670M cash/equivalents + $281.701M marketable securities.
H1 operating cash use
$141.9M
Six months ended June 30, 2026; not the quarterly figure.
ImmunityBio equity
−$1.0466B
June 30, 2026; parent stockholders’ deficit, excluding $0.868M noncontrolling interests.
Shares outstanding
1,059.84M
1,059,836,273 common shares at July 31, 2026.
Short interest
122.95M
October 15 settlement; 7.15 days to cover. A dated position measure.
Financial figures and statutory share count: June Form 10-Q and Q2 results. Market data: Nasdaq historical quotes and Nasdaq short interest. Cash and securities are distinct components; calculated market value uses a dated share count and is not a fully diluted valuation.
IBRX today: a growing approved product with capital-structure constraints
The October expansion adds high-grade papillary-only BCG-unresponsive NMIBC to the U.S. indication. The BCG-naïve program is a separate randomized trial and potential regulatory submission; its intended population is not already approved by that action. FDA approval · BCG-naïve program.
Commercial growth is real, but it does not establish self-funded operations. Q2 product revenue rose 92% year over year and 15% sequentially. The June filing discusses financing needs and reliance on planned equity funding and founder-affiliate support in addressing liquidity concerns. The June reserve alone should not be presented as a guaranteed twelve-month runway. Q2 release · Liquidity disclosure.
Main risk: Revenue growth may not offset cash consumption before new capital is needed. Clinical disappointment, slow uptake, promotional-compliance problems or unfavorable financing could weaken per-share economics despite an approved product.
Constructive case
A broader label and growing ANKTIVA sales could improve operating leverage. Favorable randomized data and successful regulatory execution may extend the addressable population, provided clinical evidence and BCG availability support adoption.
Cautious case
Large liabilities, a stockholders’ deficit, operating cash use and dilutive instruments limit the balance-sheet cushion. Broader pipeline claims and international authorizations should be evaluated separately from U.S. approvals and realized sales.
IBRX stock news: six selected updates
Oct 21, 2026
QUILT-2.005 reaches database lock
The company reported database lock for 366 randomized BCG-naïve NMIBC patients and expected topline in November, with an sBLA submission planned for Q4. No new efficacy results accompanied the procedural milestone.
Oct 16, 2026
Longer-term QUILT-3.032 results published
The company announced Journal of Urology publication of its 100-patient ANKTIVA-plus-BCG dataset, reporting 71% complete response and 84% cystectomy-free survival at 36 months among responders. This is single-arm follow-up, with a different analysis population from the FDA’s original efficacy set; the time-to-event observations do not establish a causal treatment benefit.
Oct 14, 2026
FDA expands the U.S. ANKTIVA indication
The expanded indication covers adults with BCG-unresponsive NMIBC, including high-grade papillary-only disease. The prescribing information retains the warning that delaying cystectomy can allow progression to lethal muscle-invasive or metastatic bladder cancer. BCG-naïve disease remains a separate development setting.
Oct 6, 2026
Completed insider sales are distinct from proposed sales
Cohen reported selling 81,056 shares on October 2 after exercising 55,979 options; Simon reported selling 25,000 on October 5. Both filings identify pre-existing trading plans. A broader Form 144 notice is not evidence that every proposed share was sold.
Aug 10, 2026
Jim Yong Kim appointed vice chairman
The company announced the former World Bank president’s appointment as vice chairman. A leadership appointment is separate from evidence of clinical efficacy, an authorization or a commercial contract.
Aug 4, 2026
Q2 product revenue reaches $50.7M
Net product revenue increased 92% year over year and 15% sequentially; first-half product revenue was $94.8M. Q2 operating loss was $61.7M. The $81.0M adjusted net loss is a company-defined non-GAAP measure, distinct from GAAP net loss and operating cash use.
IBRX stock catalysts: dated milestones
- November 2026 · QUILT-2.005 toplineCompany-guided window · no exact day
Randomized BCG-naïve data are the next guided clinical checkpoint. October 21 guidance.
- Q4 2026 · BCG-naïve sBLA submissionCompany plan · not an accepted application
A planned filing is separate from completed submission, FDA acceptance, a review date or approval.
- November–December 2026 · Investor and scientific conferencesCalendar listings · data presentation not inferred
The investor calendar lists SITC, SNO and other meetings. Listing an event does not announce QUILT-2.005 results there.
- January 25, 2027 · Altor CVR arbitration hearingScheduled in the June filing · contested claim
The date is disclosed in the June 10-Q; it is not a clinical catalyst or an established loss. Commitments and contingencies.
- December 31, 2027 · Related-party convertible note maturityContractual maturity disclosed in June
The filing reports $480M principal. Repayment, conversion and any renegotiation have different effects on cash and shareholders.
ANKTIVA: approved uses and evidence limits
U.S. label
BCG-unresponsive NMIBC
October approval includes high-grade papillary-only disease. ANKTIVA is used with BCG; the current label and its safety warning define the approved setting.
Next trial
BCG-naïve is separate
QUILT-2.005 compares ANKTIVA plus BCG against BCG alone. Database lock and expected topline do not constitute positive final results.
Interpretation
Single-arm limits remain
Response and follow-up observations require their actual populations and denominators. They do not establish comparative survival or cystectomy-avoidance benefit.
The January FDA untitled letter and March warning letter addressed promotional claims. The company announced remediation in April; those steps are distinct from an FDA conclusion that every compliance issue is resolved. Current label · January FDA letter · March FDA warning · Company response.
IBRX cash, share dilution and contingent claims
The June EPS note lists 167.4M potential shares under convertible instruments, warrants, options and awards; subsequent exercises change that dated total. Separately, $349.2M remained under the $500M ATM program. Potential issuance is not automatic conversion, and ATM capacity is not cash already received. The related-party note carries $480M principal due December 31, 2027.
The same filing discloses securities and derivative litigation tied to promotional statements, with allegations disputed by the company. In the Altor CVR arbitration, claimants sought approximately $164.2M plus more than $50M interest; the company disputed the claim and could not estimate the likely loss. A demand is not an established liability. The disclosed January 25, 2027 hearing and other contingencies deserve attention alongside revenue. June Form 10-Q: capital, liquidity and contingencies.
Merlintrader Health Score · IBRX
2.95out of 5
Editorial assessment dated October 29, 2026. The existing five pillar marks produce an exact weighted score of 2.95/5: 2×30% + 3.5×30% + 3×20% + 2.5×10% + 4.5×10%. This measures robustness, not valuation, a price target or an investment recommendation.
IBRX red flags
- BCG-naïve development and international indications are distinct from the U.S. approved label.
- A database lock is not a positive efficacy readout.
- Single-arm follow-up cannot establish comparative survival or cystectomy-avoidance benefits.
- Cash use and financing needs persist despite product revenue growth.
- Convertible debt, warrants, awards and ATM issuance can dilute ownership.
- FDA promotional-compliance history and contested litigation remain relevant.
- Altor CVR demands are material contested claims, not established losses.
IBRX Stock FAQ: ImmunityBio Questions Answered
When will ImmunityBio report QUILT-2.005 results?
ImmunityBio expects QUILT-2.005 topline results in November 2026, following the October 21 announcement of database lock for 366 randomized patients in Cohort A. No specific readout day was announced. An sBLA submission for the BCG-naïve setting was planned for Q4 2026. Trial-results guidance.
Is ImmunityBio’s ANKTIVA FDA approved?
Yes: ANKTIVA is FDA approved with BCG for BCG-unresponsive non-muscle invasive bladder cancer, with an October 14, 2026 label expansion adding high-grade papillary-only disease. That expansion does not cover the BCG-naïve population being studied in QUILT-2.005. FDA expanded indication. Current prescribing information.
How much cash does ImmunityBio have, and how long will it last?
ImmunityBio held $357.4 million cash and marketable securities at June 30, 2026, while first-half operating cash use was $141.9 million. Its liquidity plan includes additional equity funding and founder-affiliate support. Rising ANKTIVA sales help fund operations, but continued financing remains part of that plan. Liquidity and financing plan.
Is IBRX stock at risk of dilution?
Yes: ImmunityBio’s June 30, 2026 EPS note lists 167.4 million potential shares from convertible instruments, warrants, options and awards. Another $349.2 million remained available under its $500 million ATM program. Exercises after the reporting date change that potential-share total. Potential shares and ATM capacity.
When does ImmunityBio report earnings?
As of November 2, 2026, ImmunityBio had not announced its next quarterly earnings date. Its latest reported financial period ended June 30. The November QUILT-2.005 topline window is a clinical-data timetable, not a dated financial-results announcement. Company event calendar. Latest quarterly results.
What does ImmunityBio do?
ImmunityBio develops immunotherapies designed to activate natural killer cells and T cells against cancer. Its commercial product ANKTIVA is an interleukin-15-based immune stimulant used with BCG in bladder cancer; the company is studying additional bladder-cancer populations and other tumor types. Company and product overview. Approved treatment.
Is ImmunityBio’s Altor arbitration claim an established loss?
No: ImmunityBio’s June 30, 2026 filing describes a disputed Altor CVR demand of approximately $164.2 million plus more than $50 million interest. The company said it could not estimate the likely outcome or loss range. A hearing was scheduled for January 25, 2027. Contingency disclosure.
How much ANKTIVA revenue does ImmunityBio generate?
ImmunityBio reported $50.7 million net ANKTIVA product revenue for the quarter ended June 30, 2026, up 92% year over year and 15% sequentially. The commercial rollout is expanding alongside the October U.S. label extension. Product sales. October indication expansion.
Primary sources
- FDA October expanded indication
- October U.S. prescribing information
- QUILT-2.005 database-lock announcement
- QUILT-2.005 registry
- June Form 10-Q
- Q2 results
- QUILT-3.032 publication announcement
- January FDA untitled letter
- March FDA warning letter
- April company compliance response
- Investor calendar
- Nasdaq historical prices
- Nasdaq short interest
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $IBRX or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, approval does not guarantee commercial uptake, and development-stage companies frequently raise equity at whatever price the market will bear. A single readout can change the value of the business overnight in either direction, and companies at this stage can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.
Educational and legal disclaimer: This Merlintrader page is general editorial research for informational and educational purposes only. It is not investment advice, personalized financial advice, a recommendation, a solicitation, an offer to buy or sell securities, or a prediction of an FDA or market outcome. Nothing on this coverage is tailored to any reader’s objectives, financial situation or risk tolerance. Biotechnology securities can be highly volatile and may involve clinical, regulatory, manufacturing, commercial, financing, dilution, governance and liquidity risk, including the possible loss of invested capital. International authorizations do not automatically change the U.S. label or guarantee commercial adoption. Company-reported trial analyses, indirect comparisons and forward-looking statements are not the same as FDA findings, randomized evidence and audited results. Readers should verify all material facts against current FDA documents, SEC filings, official releases and trial records and consult appropriately authorized professionals where required under applicable U.S., Italian or other local rules.
